Raziel Therapeutics

Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for targeted fat reduction. The company has developed a new chemical entity that converts white adipose tissue (WAT) into brown adipose tissue (BAT) after a single injection into subcutaneous fat, potentially providing a new way to treat people who are overweight or obese. Raziels primary drug candidate is RZL-012, an injectable drug that is currently in preclinical development. RZL-012 is administered by several injections delivered in a single injection session. Once injected, RZL-012 triggers immediate fat-cell death, followed by a transient inflammatory process that lasts about a month during which necrotic fat tissue is replaced by fibrotic tissue. This results in a significant long-term, sustained shrinkage of fat tissue. The companys products are based on work by the team led by Professor Muli Ben-Sasson, who discovered a family of compounds that are able to influence the fate of fat-tissue cells (adipocytes) and convert them from WAT to BAT tissues. In November 2019, Raziel received FDA approval to develop RZL-012 as an orphan drug for Dercums disease.

Raziel Therapeutics has raised $27.1M in total funding across 4 rounds. The company is currently at the C stage. Key investors include Peregrine Ventures, Pontifax, Quark Venture.

Raziel Therapeutics operates in Health Tech & Life Sciences, Pharma & Medical Biotechnology, Drugs Discovery & Development, with core technologies in Biologicals. Target customers: Healthcare & Life Sciences, Healthcare, Patients, Life Sciences, Pharmaceuticals.

Raziel Therapeutics is based in Prof. Menahem Plaut Street 10, Rehovot, Israel, Center District.